A two‐part, single‐arm, multicentre, phase I study of zanubrutinib, a selective Bruton tyrosine kinase inhibitor, in Chinese patients with relapsed/refractory B‐cell malignancies

This single‐arm, multicentre, phase I study is the first study of zanubrutinib, a potent, specific, irreversible Bruton tyrosine kinase (BTK) inhibitor, in Chinese patients with relapsed/refractory B‐cell malignancies. The objectives were to evaluate safety and preliminary anti‐tumour activity. Fort...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Yuqin, Sun, Mingyuan, Qi, Junyuan, Xu, Wei, Zhou, Jianfeng, Li, Dengju, Li, Jianyong, Qiu, Lugui, Du, Chenmu, Guo, Haiyi, Huang, Jane, Tang, Zhiyu, Ou, Ying, Wu, Binghao, Yu, Yiling, Zhu, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Haematological Malignancy‐clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9321909/
https://www.ncbi.nlm.nih.gov/pubmed/35383885
http://dx.doi.org/10.1111/bjh.18162

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9321909/
https://www.ncbi.nlm.nih.gov/pubmed/35383885
http://dx.doi.org/10.1111/bjh.18162

Ejemplares similares